Because AR reduces glucose in its role as an important enzyme in the polyol pathway, previous studies have reported that the inhibition of AR is involved in the action of Kampo medicines that are used for treatment of DN including Goshajinkigan, Hachimijiogan, Sokeikakketuto and Keishikajutsubuto [19]. This evidence concerns the gene AR and liver dysplastic nodule.